Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
NCT00621270
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
115
Enrollment
INDUSTRY
Sponsor class
Conditions
Major Depressive Disorder
Anxiety
Interventions
DRUG:
BCI-540
Sponsor
BrainCells Inc.